C 103

Drug Profile

C 103

Alternative Names: C-103; Orlistat reformulated - Callitas Therapeutics

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chelatexx
  • Developer Callitas Therapeutics
  • Class Anorectics; Lactones
  • Mechanism of Action Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Obesity

Most Recent Events

  • 30 Jun 2017 C 103 is available for licensing as of 30 Jun 2017. http://m-pharma.ca/
  • 31 May 2017 M Pharmaceutical receives positive response from the FDA for pre-IND meeting of C 103
  • 10 Feb 2017 M Pharmaceutical completes pre-IND meeting for C 103
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top